MergerMay 15, 2026, 04:29 PM
RIBB Enters Business Combination Agreement with DRC Medicine
AI Summary
Ribbon Acquisition Corp. (RIBB) announced a definitive Business Combination Agreement with DRC Medicine Inc., a company focused on AI-powered allergy and infection diagnostic kits, valuing the target at $350 million. Shareholders also approved an extension of the business combination period to January 16, 2027, which led to the redemption of 1,436,867 public shares for $14.94 million. For the first quarter of 2026, the company reported a net income of $252,755, an increase from the prior year, but also noted a working capital deficit of $1.01 million and a significant decrease in cash held in the trust account.
Key Highlights
- Entered Business Combination Agreement with DRC Medicine Inc. for $350M Equity Value.
- Shareholders approved extension to January 16, 2027, with $125,000 monthly payments.
- 1,436,867 public shares redeemed for $14,937,326, at ~$10.40 per share.
- Net income for Q1 2026 was $252,755, up from $235,856 in Q1 2025.
- Cash and marketable securities in trust account decreased to $37.72M from $51.95M.
- Reported a working capital deficit of $1,008,960 as of March 31, 2026.
- Accumulated deficit increased to $355,267 from $344,465 as of Dec 31, 2025.
- Net cash used in operating activities was $9,619 for Q1 2026.
Price Impact
More from RIBB